Trial Profile
A Phase 1, Randomized, Open-Label, Parallel-Design, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Capsules in Infants Aged 1 to 11 Months With Acid-Related Diseases
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dexlansoprazole (Primary)
- Indications Erosive oesophagitis; Gastro-oesophageal reflux
- Focus Pharmacokinetics
- Sponsors Takeda
- 08 Jul 2020 This trial was completed in Poland as per European clinical trial database record (global end of the trial 2020-02-10).
- 13 Apr 2020 Status changed from suspended to withdrawn prior to enrolment.
- 03 Oct 2019 Planned End Date changed from 23 Dec 2020 to 23 Dec 2025.